GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program
This article was originally published in The Pink Sheet Daily
Executive Summary
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.